Key Insights

Highlights

Success Rate

88% trial completion (above average)

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 40/100

Termination Rate

6.4%

3 terminated out of 47 trials

Success Rate

88.5%

+2.0% vs benchmark

Late-Stage Pipeline

15%

7 trials in Phase 3/4

Results Transparency

26%

6 of 23 completed with results

Key Signals

6 with results88% success

Data Visualizations

Phase Distribution

28Total
Not Applicable (6)
P 1 (9)
P 2 (6)
P 3 (1)
P 4 (6)

Trial Status

Completed23
Unknown15
Recruiting3
Terminated3
Withdrawn1
Active Not Recruiting1

Trial Success Rate

88.5%

Benchmark: 86.5%

Based on 23 completed trials

Clinical Trials (47)

Showing 20 of 20 trials
NCT04659343Recruiting

TDM for Optimized Outcome in Patients With mRCC.

NCT07008027Not Yet RecruitingPrimary

Real World Asparaginase Therapy Toxicity

NCT04305145Phase 2Active Not Recruiting

Infliximab for Treatment of Immune Checkpoint Inhibitor Colitis

NCT05512169Recruiting

Pharmacogenomic Association Study in Indian Children With Acute Lymphoblastic Leukemia

NCT03461445Phase 4Completed

Effect of Tacrolimus Formulation on Neurological Side Effects in Older Kidney Transplant Recipients

NCT05691309Completed

Optimizing Vancomycin Therapy in Children

NCT03651778CompletedPrimary

GHB Poisoning and Poisoning Induced by Others

NCT04696081Recruiting

Atrial Fibrillation in Active Cancer Patients

NCT01135680Phase 1CompletedPrimary

Double-Blind Randomized Crossover Trial to Access Electrocardiogram Effects of HPN-100

NCT05022797Phase 2Terminated

Reduction of MTX Levels After Glucarpidase Treatment in DLBCL Patients at Risk of CNS

NCT05899751Unknown

Retrospective Registry Study of Patients With Cancer Treated With High-dose Methotrexate

NCT06214468Phase 1UnknownPrimary

Protective Effect of Nicotinamide Riboside Against Acetaminophen Toxicity

NCT05237492Phase 4CompletedPrimary

The Influence of Tramadol on Platelet Function

NCT06019520Not ApplicableUnknownPrimary

Role of N-Acetylcysteine for Prevention of Cisplatin-induced Nephrotoxicity

NCT03265613Phase 1Completed

Safety and Efficacy of Expanded Allogeneic AD-MSCs in Patients With Moderate to Severe Psoriasis

NCT04275024Not ApplicableCompleted

Efficacy and Safety of AD-MSCs Plus Calpocitriol Ointment and PSORI-CM01 Granule in Psoriasis Patients

NCT03392311Phase 1Completed

Efficacy and Safety of AD-MSCs Plus Calpocitriol Ointment in Patients With Moderate to Severe Psoriasis

NCT05851222Unknown

A Big Data Approach to Predict NEOnatal Acute Kidney Injury in Newborns expoSed to nephroTOxic Drugs (NeoAKI STOP)

NCT03994302Completed

Monitoring the Antiphospholipid Syndrome:TOXicity of Drugs (APSTOX)

NCT03947034Completed

Monitoring the Hyperammonaemia:TOXicity of Drugs (AmmoTOX)

Scroll to load more

Research Network

Activity Timeline